TNF-α inhibitors: Are they carcinogenic?

Girindra Raval, Paulette Mehta

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the initiation of anti- TNF therapy. With increasing case reports, there is growing concern that anti-TNF therapy, albeit useful in the treatment of these chronic conditions, might be associated with the development of malignancy in patients. In this review we examine the different anti-TNF agents and different studies to evaluate any possible association between use of any anti-TNF agent and development of malignancy.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalDrug, Healthcare and Patient Safety
Issue number1
StatePublished - 2010
Externally publishedYes


  • Inflammatory bowel disease
  • Malignancy
  • Rheumatoid arthritis
  • Tumor necrosis factor inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy


Dive into the research topics of 'TNF-α inhibitors: Are they carcinogenic?'. Together they form a unique fingerprint.

Cite this